C4 Therapeutics is focused on developing drugs to degrade harmful proteins that cause diseases like cancer and neurodegenerative conditions. Their main product under trial is CFT7455 that targets multiple myeloma and other non-Hodgkin lymphomas. The company has strategic collaborations with well-known brands like Biogen, F. Hoffmann-La Roche, and Calico Life Sciences.